ZipRecruiter

Log In

1

Associate Director Toxicology Jobs (NOW HIRING)

next page

Showing results 1-20

All JobsHealthcare JobsMedical Specialists JobsPathology Technologist JobsAssociate Director Toxicology Jobs

Associate Director Toxicology information

See salary details

$30.5K

$102.7K

$173K

How much do associate director toxicology jobs pay per year?

As of Sep 7, 2026, the average yearly pay for associate director toxicology in the United States is $102,728.00, according to ZipRecruiter salary data. Most workers in this role earn between $70,000.00 and $141,000.00 per year, depending on experience, location, and employer.

What is the difference between Associate Director Toxicology vs Senior Toxicologist?

AspectAssociate Director ToxicologySenior Toxicologist
Required CredentialsAdvanced degree (PhD or MS), relevant certificationsTypically PhD or MS, relevant certifications
Work EnvironmentLeadership role overseeing teams, strategic planningHands-on research, data analysis, project execution
Employer & Industry UsagePharmaceutical, biotech, CROs, regulatory agenciesResearch labs, pharmaceutical companies, CROs

The Associate Director Toxicology typically holds a leadership position with strategic responsibilities, overseeing teams and projects, while the Senior Toxicologist focuses more on hands-on research and data analysis. Both roles require similar credentials and are common in the pharmaceutical and biotech industries, but the Associate Director has a broader managerial scope.

More about Associate Director Toxicology jobs

What cities are hiring for Associate Director Toxicology jobs?

Cities with the most Associate Director Toxicology job openings:

What states have the most Associate Director Toxicology jobs?

States with the most job openings for Associate Director Toxicology jobs include:

What job categories do people searching Associate Director Toxicology jobs look for?

The top searched job categories for Associate Director Toxicology jobs are:

Associate Director Toxicology jobs near you
Infographic showing various Associate Director Toxicology job openings in the United States as of August 2026, with employment types broken down into 1% As Needed, 70% Full Time, 27% Part Time, 1% Temporary, and 1% Contract. Highlights an 97% Physical, 1% Hybrid, and 2% Remote job distribution, with an average salary of $102,728 per year, or $49.4 per hour.

Associate Director, Toxicology

Protagonist Therapeutics

Newark, CA • On-site

$185K - $205K/yr

Full-time

Re-posted 29 days ago

Key responsibilities

  • Lead and manage CRO and consultant activities supporting drug research and development.

  • Develop nonclinical toxicology strategies and oversee GLP and non-GLP studies.

  • Prepare and review toxicology components of regulatory submissions and respond to regulatory inquiries.

Job description

Associate Director, Toxicology, Nonclinical Development (Program Toxicologist)
Position Description:
Protagonist Therapeutics is seeking a talented, highly motivated professional to join the Toxicology, Nonclinical Development team as Associate Director Toxicology, Nonclinical Development (Program Toxicologist). This role will lead and manage CRO and consultant activities that support drug research and development across the PTGX pipeline. The successful candidate will be responsible for developing nonclinical toxicology strategies, overseeing GLP and non-GLP studies, preparing toxicology components of regulatory submissions, and responding to inquiries from regulatory authorities. This position will report to the Senior Vice President, Toxicology, Nonclinical Development.
Responsibilities:
  • ​Serve as a self-directed toxicology leader and key member of a dynamic team supporting PTGX drug discovery and development programs.
    Independently develop phase-appropriate nonclinical toxicology strategies for PTGX pipeline molecules and represent toxicology on cross-functional project teams.
  • Design, revise, and finalize nonclinical toxicology study protocols, study designs, data analyses, and reports, including plans that support first-in-human and later-stage clinical development.
  • Prepare and critically review nonclinical toxicology sections for IND, CTA, NDA, and other regulatory submissions, ensuring alignment with applicable US and ex-US regulatory expectations.
  • Identify, evaluate, and resolve program-specific toxicology issues in collaboration with the supervisor, project teams, CROs, consultants, and other subject-matter experts.
  • Critically review and edit CRO nonclinical toxicology and related study reports, including pharmacology, ADME, PK/TK, safety pharmacology, and pathology reports; analyze and interpret data; and coordinate report finalization.
  • Ensure study documentation and regulatory deliverables are scientifically sound, timely, and consistent with global regulatory and compliance requirements.
  • Manage and monitor GLP and non-GLP nonclinical studies conducted at CROs in accordance with PTGX vendor management SOPs and policies, ensuring quality, timelines, and regulatory compliance are met or exceeded.
  • Provide clear analysis, interpretation, and visualization of nonclinical toxicology and related data for internal communications, program team presentations, regulatory interactions, and decision-making.
  • Maintain current knowledge of relevant scientific literature, methodologies, regulatory guidance, and emerging best practices applicable to PTGX pipeline products and nonclinical development programs.
Qualifications:
  • PhD or DVM in biological sciences, toxicology, pharmacology, or a related discipline.
  • DABT board certification is preferred.
  • Minimum of 5–10 years of relevant drug development experience, preferably in the biotechnology or pharmaceutical industry.
  • Demonstrated experience developing and executing nonclinical toxicology strategies that support IND-enabling studies, first-in-human clinical trials, and later-stage development programs.
  • Strong working knowledge of Good Laboratory Practice regulations and relevant FDA, ICH, OECD, EMA, and other global nonclinical safety guidelines.
  • Experience in preclinical development, toxicology, nonclinical pharmacology, drug metabolism, pharmacokinetics, and toxicokinetics.
  • Proven ability to manage CROs, consultants, and external academic or industry collaborators, including oversight of study design, budgets, timelines, monitoring, data review, and final reports.
  • Broad and integrated understanding of pharmacology, toxicology, DMPK, safety pharmacology, pathology, and translational safety assessment.
  • Excellent verbal and written communication skills, with the ability to build strong working relationships with internal colleagues, cross-functional teams, external vendors, and consultants.
  • Strong scientific background, preferably demonstrated through peer-reviewed publications, regulatory writing experience, or presentations in relevant medical and life science forums.
  • Excellent decision-making, complex problem-solving, critical thinking, data analysis, and data interpretation skills.
  • Highly motivated, flexible, and proactive self-starter who takes ownership of new tasks and delivers high-quality results with limited supervision.
  • Demonstrated ability to be productive and successful in a fast-paced, matrixed, and multi-tasking work environment.
The base pay range for this position at commencement of employment is expected to be between $185K and $205K / year; however, base pay offered may vary depending on multiple individualized factors, including market location, job-related knowledge, skills, and experience.
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. The Company's proprietary peptide technology platform enables de novo discovery of peptide therapeutics. Two novel peptides derived from Protagonist's proprietary discovery platform are at or near commercialization. ICOTYDE™ (icotrokinra) is approved in the U.S. for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy. ICOTYDE is the first and only targeted oral peptide that precisely blocks the Interleukin-23 receptor (IL-23R) licensed to Janssen Biotech, Inc.,a Johnson amp; Johnson company. ICOTYDE was jointly discovered by Protagonist and Johnson amp; Johnson scientists, with Protagonist having primary responsibility for the development of ICOTYDE through Phase 1, and Johnson amp; Johnson assuming responsibility for further development and commercialization. An NDA for rusfertide, a first-in-class hepcidin mimetic peptide that is being co-developed with Takeda Pharmaceuticals pursuant to a worldwide license and collaboration agreement entered in 2024, is under priority review with the FDA. Protagonist holds an option to co-commercialize rusfertide in the U.S. through a 50/50 profit and loss share structure or can opt-out of this structure. The Company also has a number of preclinical stage drug discovery programs addressing clinically and commercially validated targets including an oral IL-17 peptide antagonist, obesity dual and triple agonists, an oral hepcidin functional mimetic, and the recently announced IL-4 and amylin programs.
More information on Protagonist, its pipeline drug candidates, and clinical studies can be found on the Company's website at https://www.protagonist-inc.com.

Apply